We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022

Continue

Cancel

Our Science

The Core of Who We Are

With more than 70 years of expertise in Neuroscience, Lundbeck has developed and commercialised some of the world’s most widely prescribed therapies for brain diseases. Behind the science lies dedicated researchers, novel ideas, and a passion to make a difference.

Research and Development

R&D of new and improved treatments is at the core of what we do. More than 800 employees work in our state-of-the-art R&D units in Denmark and California, US.

Products

Our products, registered in more than 100 countries, are the proud results of years of research – reaching roughly 50 million people yearly.

Pipeline

Our pipeline reflects our goal to deliver novel therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest need.

Lundbeck registers clinical trial protocols and discloses the results of clinical trials, regardless of outcome in a publicly accessible trial registry.

Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling our purpose.

Medical Education

We provide evidence-based medical education and training for healthcare professionals via the Lundbeck Institute, Lundbeck Institute Campus and Progress in Mind Resource Centre.  

Scientific Partnerships

The complexity of brain diseases requires a concerted effort and approach. We are committed to developing new and improved treatment options from innovations born in-house or externally.

UK-NOTPR-0538 | April 2022